ROIV Roivant Sciences: Business Value to Revenue

Official company branding of roivant.com (ROIV)

Roivant Sciences Ltd. (ROIV) generates revenue through the commercialization of innovations, primarily driven by sales of the VTAMA cream. The enterprise value assessment via EV/Sales demonstrates the business's resilience to shocks, with 601346.15 serving as the current value of this metric. The holding company model relies on the autonomy of scientist-entrepreneurs, while diversification through the "Vants" network minimizes risks associated with FDA regulatory approvals.

Roivant Sciences Ltd. (ROIV): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Roivant - analytical breakdowns and key metrics (ROIV)

- stock value and consensus price forecast:
- company stock capitalization data:
- cash balance and cash flow data:
Initial company analysis:Roivant Sciences, ROIV
Flagship merchandise of Roivant Sciences

Roivant Sciences Ltd. (ROIV) monetizes its Vant strategy by reviving undervalued big pharma molecules to create high-margin therapeutic products. By analyzing the business valuation via EV/Sales, an investor sees the ratio of enterprise value minus debt to annual revenue, which allows for an assessment of market expectations for future sales. The dynamics of this indicator reflect the balance between the risk of overpayment and the potential for capitalization growth upon the launch of new drugs.